Identification of a basement membrane-based risk scoring system for prognosis prediction and individualized therapy in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) belongs to one of the 10 most frequently diagnosed cancers worldwide and has a poor prognosis at the advanced stage. Although multiple therapeutic agents have been proven to be curative in ccRCC, their clinical application was limited due to the lack of reliable biomarkers. Considering the important role of basement membrane (BM) in tumor metastasis and TME regulation, we investigated the expression of BM-related genes in ccRCC and identified prognostic BM genes through differentially expression analysis and univariate cox regression analysis. Then, BM-related ccRCC subtypes were recognized through consensus non-negative matrix factorization based on the prognostic BM genes and evaluated with regard to clinical and TME features. Next, utilizing the differentially expressed genes between the BM-related subtypes, a risk scoring system BMRS was established after serial analysis of univariate cox regression analysis, lasso regression analysis, and multivariate cox regression analysis. Time-dependent ROC curve revealed the satisfactory prognosis predictive capacity of BMRS with internal, and external validation. Multivariate analysis proved the independent predictive ability of BMRS and a BMRS-based nomogram was constructed for clinical application. Some featured mutants were discovered through genomic analysis of the BMRS risk groups. Meanwhile, the BMRS groups were found to have distinct immune scores, immune cell infiltration levels, and immune-related functions. Moreover, with the help of data from The Cancer Immunome Atlas (TCIA) and Genomics of Drug Sensitivity in Cancer (GDSC), the potential of BMRS in predicting therapeutic response was evaluated and some possible therapeutic compounds were proposed through ConnectivityMap (CMap). For the practicability of BMRS, we validated the expression of BMRS-related genes in clinical samples. After all, we identified BM-related ccRCC subtypes with distinct clinical and TME features and constructed a risk scoring system for the prediction of prognosis, therapeutic responses, and potential therapeutic agents of ccRCC. As ccRCC systemic therapy continues to evolve, the risk scoring system BMRS we reported may assist in individualized medication administration.

[1]  C. Chen,et al.  Characterization of the basement membrane in kidney renal clear cell carcinoma to guide clinical therapy , 2022, Frontiers in Oncology.

[2]  Tao Zhou,et al.  A newly defined basement membrane-related gene signature for the prognosis of clear-cell renal cell carcinoma , 2022, Frontiers in Genetics.

[3]  Hailang Zhou,et al.  miR-1266-3p Suppresses Epithelial-Mesenchymal Transition in Colon Cancer by Targeting P4HA3 , 2022, Analytical cellular pathology.

[4]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  OUP accepted manuscript , 2022, Journal of Molecular Cell Biology.

[6]  In‐San Kim,et al.  Rho-Kinase as a Target for Cancer Therapy and Its Immunotherapeutic Potential , 2021, International journal of molecular sciences.

[7]  D. Smedley,et al.  A basement membrane discovery pipeline uncovers network complexity, regulators, and human disease associations , 2021, bioRxiv.

[8]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[9]  Wei Wang,et al.  HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration. , 2021, International immunopharmacology.

[10]  M. Tomita,et al.  TGF-β-dependent reprogramming of amino acid metabolism induces epithelial–mesenchymal transition in non-small cell lung cancers , 2021, Communications Biology.

[11]  Yue He,et al.  A novel era of cancer/testis antigen in cancer immunotherapy. , 2021, International immunopharmacology.

[12]  Bin Zhao,et al.  Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy , 2021, npj Precision Oncology.

[13]  M. Ligtenberg,et al.  Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity , 2021, Cancers.

[14]  M. Remzi,et al.  First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. , 2021, European urology oncology.

[15]  Jia Wei,et al.  Gene fusion neoantigens: Emerging targets for cancer immunotherapy. , 2021, Cancer letters.

[16]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[17]  B. Porse,et al.  Basement membrane stiffness determines metastases formation , 2021, Nature Materials.

[18]  P. Hegde,et al.  Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. , 2020, Cancer cell.

[19]  Bartłomiej Borek,et al.  Boronic acid-based arginase inhibitors in cancer immunotherapy. , 2020, Bioorganic & medicinal chemistry.

[20]  S. Hancock,et al.  NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  B. Rini,et al.  The immunology of renal cell carcinoma , 2020, Nature Reviews Nephrology.

[22]  R. Stephens,et al.  ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications , 2020, Scientific Reports.

[23]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[24]  S. H. van der Burg,et al.  The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment , 2020, Clinical Cancer Research.

[25]  Xueli Zhang,et al.  The endothelial basement membrane acts as a checkpoint for entry of pathogenic T cells into the brain , 2020, The Journal of experimental medicine.

[26]  G. Freeman,et al.  The importance of exosomal PDL1 in tumour immune evasion , 2020, Nature Reviews Immunology.

[27]  Ovijit Chaudhuri,et al.  Beyond proteases: Basement membrane mechanics and cancer invasion , 2019, The Journal of cell biology.

[28]  D. Adah,et al.  CXCL13/CXCR5 signaling axis in cancer. , 2019, Life sciences.

[29]  Y. Niu,et al.  β-Catenin nuclear localization positively feeds back on EGF/EGFR-attenuated AJAP1 expression in breast cancer , 2019, Journal of experimental & clinical cancer research : CR.

[30]  Haiyang Xie,et al.  HJURP Promotes Epithelial-to-Mesenchymal Transition via Upregulating SPHK1 in Hepatocellular Carcinoma , 2019, International journal of biological sciences.

[31]  S. Germain,et al.  Extracellular matrix scaffolding in angiogenesis and capillary homeostasis. , 2019, Seminars in cell & developmental biology.

[32]  C. Nimsky,et al.  ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance. , 2019, Clinical science.

[33]  H. Hammers,et al.  The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma , 2019, Front. Immunol..

[34]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[35]  Robert B West,et al.  Matrix mechanical plasticity regulates cancer cell migration through confining microenvironments , 2018, Nature Communications.

[36]  Lieping Chen,et al.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.

[37]  Chao Li,et al.  P4HA3 is Epigenetically Activated by Slug in Gastric Cancer and its Deregulation is Associated With Enhanced Metastasis and Poor Survival , 2018, Technology in cancer research & treatment.

[38]  Yan Zhang,et al.  Fifteen-gene expression based model predicts the survival of clear cell renal cell carcinoma , 2018, Medicine.

[39]  C. Klein,et al.  A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Medicine.

[40]  S. Adams,et al.  Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes , 2018, Molecular Cancer Therapeutics.

[41]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[42]  M. Hellmann,et al.  Adverse Events Associated with Immune Checkpoint Blockade. , 2018, The New England journal of medicine.

[43]  Jiuyong Li,et al.  CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization , 2017, Bioinform..

[44]  S. Signoretti,et al.  Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. , 2017, The oncologist.

[45]  H. T. Aiyelabegan,et al.  Role of protease and protease inhibitors in cancer pathogenesis and treatment. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[46]  R. Motzer,et al.  Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[47]  J. Cheville,et al.  Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  A. Pozzi,et al.  The nature and biology of basement membranes. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[49]  B. Donnelly,et al.  Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients , 2016, Journal of Molecular Medicine.

[50]  T. Eisen,et al.  Medical treatment of renal cancer: new horizons , 2016, British Journal of Cancer.

[51]  A. Tzankov,et al.  The immune system and cancer evasion strategies: therapeutic concepts , 2016, Journal of internal medicine.

[52]  P. Murray,et al.  MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome. , 2016, Cancer research.

[53]  P. Heneberg.  Paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts. , 2016, Critical reviews in oncology/hematology.

[54]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[55]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[56]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[57]  W. Rathmell,et al.  Renal cell carcinoma , 2014, BMJ : British Medical Journal.

[58]  M. Karin,et al.  Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts , 2014, Proceedings of the National Academy of Sciences.

[59]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[60]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[61]  Robert M. Hoffman,et al.  Physical limits of cell migration: Control by ECM space and nuclear deformation and tuning by proteolysis and traction force , 2013, The Journal of cell biology.

[62]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[63]  Eli Gilboa,et al.  The determinants of tumour immunogenicity , 2012, Nature Reviews Cancer.

[64]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[65]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[66]  P. Yurchenco.  Basement membranes: cell scaffoldings and signaling platforms. , 2011, Cold Spring Harbor perspectives in biology.

[67]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[68]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[69]  J. Gallo,et al.  Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. , 2009, Neuro-oncology.

[70]  Chuan Wu,et al.  Endothelial basement membrane laminin α5 selectively inhibits T lymphocyte extravasation into the brain , 2009, Nature Medicine.

[71]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[72]  B. Rini,et al.  Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients , 2008, Clinical Cancer Research.

[73]  J. Gallo,et al.  Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide , 2008, Clinical Cancer Research.

[74]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[75]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[76]  B. Engelhardt,et al.  Endothelial Cell Laminin Isoforms, Laminins 8 and 10, Play Decisive Roles in T Cell Recruitment across the Blood–Brain Barrier in Experimental Autoimmune Encephalomyelitis , 2001, The Journal of cell biology.

[77]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.